REFERENCES
- National Alliance for Model State Drug Laws. Prescription drug monitoring programs: a brief overview national alliance for model state drug laws (NAMSDL). 2011. Available at: http://www.namsdl.org/documents/BriefOverviewPMPLaws-9-27-11.pdf. Accessed November 1, 2011.
- Alliance of States with Prescription Monitoring Programs. Prescription monitoring programs frequently asked questions (FAQ). 2012. Available at: http://www.pmpalliance.org/ content/prescription-monitoring-frequently-asked-questions-faq. Accessed November 14, 2012.
- Drug Enforcement Administration. Prescription Drug Monitoring Programs (Questions and Answers). 2011. Available at: http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm#10. Accessed September 29, 2011.
- United States General Accounting Office. Prescription drugs state monitoring programs provide useful tool to reduce diversion. 2002. Available at: http://purl.access.gpo.gov/GPO/ LPS38291. Accessed July 2, 2011.
- Blumenschein K, Fink JL, Freeman PR, Review of prescription drug monitoring programs in the United States. 2010. Available at: http://chfs.ky.gov/NR/rdonlyres/85989824- 1030-4AA6-91E1-7F9E3EF68827/0/KASPEREvaluation PDMPStatusFinalReport6242010.pdf. May 3, 2011.
- Katz N, Houle B, Fernandez KC, Update on prescription monitoring in clinical practice: a survey study of prescription monitoring program administrators. Pain Med. 2008;9:587–594.
- Alliance of States with Prescription Monitoring Programs. Status of prescription monitoring programs. 2012. Available at: http://www.pmpalliance.org/content/prescription-monitoring-frequently-asked-questions-faq. Accessed July 19, 2012.
- National Alliance for Model State Drug Laws. States that provide PMP database information to prescribers and dispensers. Available at: http://www.namsdl.org/documents/States thatProvidePMPInfotoPrescribersandDispensers09182012.pdf. updated September 2012. Accessed November 11, 2012.
- Washington State Department of Health. Prescription Monitoring Program. Frequently Asked Question. 2011. Available at: http://www.doh.wa.gov/hsqa/PMP/providers.htm. Accessed June 10, 2012.
- National Alliance for Model State Drug Laws. Prescription drug monitoring programs: a brief overview of National Alliance for Model State Drug Laws (NAMSDL). 2010. Available at: http://www.namsdl.org/documents/PMPsBriefOverview8- 17-2010.pdf. Accessed August 17, 2010.
- Manchikanti L. National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician. 2007;10:399–424.
- Simeone R, Holland L. An evaluation of prescription drug monitoring programs. September 1, 2006. Available at: http://www.simeoneassociates.com/simeone3.pdf. Accessed August 10, 2010.
- Green TC, Mann MR, Bowman SE, How does use of a prescription monitoring program change medical practice? Pain Med. 2012;13:1314–1323.
- Reifler LM, Droz D, Bailey JE, Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13:434–442.
- Barrett K, Watson A. Physician perspectives on a pilot prescription monitoring program. J Pain Palliat Care Pharmacother. 2005;19:5–13.
- Perrone J, DeRoos FJ, Nelson LS. Prescribing practices, knowledge, and use of prescription drug monitoring programs (PDMP) by a national sample of medical toxicologists, 2012. J Med Toxicol. 2012;8:341–352.
- Feldman L, Williams KS, Coates J, Knox M. Awareness and utilization of a prescription monitoring program among physicians. J Pain Palliat Care Pharmacother. 2011;25:313–317.
- LeMire SD, Martner SG, Rising C. Advanced practice nurses’ use of prescription drug monitoring program information. J Nurse Pract. 2012;8:383–388, 405.
- Blumenschein K, Fink JL, Freeman PR, Kirsh KL, Steinke DT, Talbert JC. Independent evaluation of the impact and effectiveness of the Kentucky All Schedule Prescription Electronic Reporting Program (KASPER). 2010. Available at: http://chfs.ky.gov/NR/rdonlyres/24493B2E-B1A1-4399- 89AD-1625953BAD43/0/KASPEREvaluationFinalReport 10152010.pdf. November 10, 2010.
- Farris KB, Schopflocher DP. Between intention and behavior: an application of community pharmacists’ assessment of pharmaceutical care. Soc Sci Med. 1999;49:55–66.
- Wixson SE, Talbert J, Blumenschein K, Freeman PR. Impact of prescription monitoring programs on pharmacists’ controlled substance dispensing behavior. Value Health. 2012;15:A29–A30.
- Ulbrich TR, Dula CA, Green CG, Porter K, Bennett MS. Factors influencing community pharmacists’ enrollment in a state prescription monitoring program. J Am Pharm Assoc. 2010;50:588–594.
- Perrone J, Nelson LS. Medication reconciliation for controlled substances–an “ideal” prescription-drug monitoring program. N Engl J Med. 2012;366:2341–2343.
- Reifler LM, Droz D, Bailey JE, Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13:434–442.
- Dormuth CR, Miller TA, Huang A, Mamdani MM, Juurlink DN. Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines. CMAJ. 2012;184:E852–E856.
- Baehren DF, Marco CA, Droz DE, Sinha S, Callan EM, Akpunonu P. A statewide prescription monitoring program affects emergency department prescribing behaviors. Ann Emerg Med. 2010;56:19–23.e13.
- Clark T, Eadie J, Kreiner P, Strickler G. Prescription drug monitoring programs: an assessment of the evidence for best practices. 2012. Available at: http://www.pewhealth.org/ uploadedFiles/PHG/Content_Level_Pages/Reports/PDMP_ Full%20and%20Final.pdf. Accessed October 10, 2012.
- Sorg M, LaBrie S, Parker W. Analysis and evaluation of participation by prescribers and dispensers in the Maine state prescription monitoring program. 2009. Available at: http:// mcspolicycenter.umaine.edu/files/pdf/PMP%20Report%20 Final%20Nov09.pdf Accessed July 24, 2012.
- Simoni-Wastila L, Ross-Degnan D, Mah C, A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in Medicaid patients with chronic psychiatric and neurologic disorders. Clin Ther. 2004;26:322–336.
- Paulozzi LJ, Stier DD. Prescription drug laws, drug overdoses, and drug sales in New York and Pennsylvania. J Public Health Policy. 2010;31:422–432.
- Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12:657–667.
- Coalition Against Insurance Fraud. Prescription for peril: how insurance fraud finances theft and abuse of addictive prescription drugs. 2007. Available at: http://www.insurancefraud.org/ downloads/drugDiversion.pdf. Accessed November 5, 2011.